The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
 
Syed Arsalan Ahmed Naqvi
No Relationships to Disclose
 
Irbaz Bin Riaz
No Relationships to Disclose
 
Huan He
No Relationships to Disclose
 
Manal Imran
No Relationships to Disclose
 
Jacob Orme
Patents, Royalties, Other Intellectual Property - Patents regarding PD-L1 cleavage and immunotherapy resistance in multiple cancers. (Inst)
 
Daniel S Childs
Honoraria - IntrinsiQ; Targeted Oncology
Consulting or Advisory Role - Janssen Biotech (Inst)
Research Funding - Janssen Biotech (Inst)
 
Praful Ravi
No Relationships to Disclose
 
Syed A. Hussain
No Relationships to Disclose
 
Parminder Singh
Honoraria - Curio Science; Medpage/ASCO
Consulting or Advisory Role - AVEO; Bayer; EMD Serono; Janssen Oncology; Seattle Genetics/Astellas (Inst)
Research Funding - EMD Serono (Inst)
(OPTIONAL) Uncompensated Relationships - Seagen
 
Alan Haruo Bryce
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Castle Biosciences; Horizon CME; Myovant Sciences; Myovant Sciences; Pfizer; Research to Practice; Research to Practice; Verity Pharmaceuticals
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Clovis Oncology (Inst); Phosplatin Therapeutics (Inst)